Rifamycin SV MMX for the treatment of traveler's diarrhea

被引：2
|
作者：
Lin, Shu-Wen [1 ,2 ,3 ]
Lin, Chun-Jung [1 ,2 ]
Yang, Jyh-Chin [4 ]
机构：
[1] Natl Taiwan Univ, Grad Inst Clin Pharm, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
[4] Natl Taiwan Univ, Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2017年 / 18卷 / 12期
关键词：
Infectious diarrhea; non-absorbable antibiotics; rifamycin SV MMX; traveler's diarrhea; ANION TRANSPORTING POLYPEPTIDES; ESCHERICHIA-COLI; DOUBLE-BLIND; GASTROINTESTINAL TRANSIT; INFECTIOUS DIARRHEA; YOUNG-CHILDREN; RIFAXIMIN; RELEASE; PLACEBO; LOPERAMIDE;
D O I：
10.1080/14656566.2017.1353079
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Rifamycin SV MMX (R), a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies.Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea.Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine's efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination.
引用
收藏
页码：1269 / 1277
页数：9
相关论文
共 50 条
12345